These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 2177401

  • 21. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL.
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [Abstract] [Full Text] [Related]

  • 22. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.
    Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH.
    Drug Metab Dispos; 1990; 18(6):1005-10. PubMed ID: 1981505
    [Abstract] [Full Text] [Related]

  • 23. [Influence of new quinolones on superoxide anion generation of polymorphonuclear leukocytes].
    Mitani H, Kiyota H.
    Kansenshogaku Zasshi; 1992 Jan; 66(1):59-65. PubMed ID: 1328418
    [Abstract] [Full Text] [Related]

  • 24. Meta-analysis of quinolone-theophylline interactions.
    Parent M, LeBel M.
    DICP; 1991 Feb; 25(2):191-4. PubMed ID: 1647570
    [Abstract] [Full Text] [Related]

  • 25. [Study on the molecular mechanism of quinolone resistance in Shigellae spp].
    Zhu JY, Duan GC, Xi YL.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Mar; 25(3):245-7. PubMed ID: 15200940
    [Abstract] [Full Text] [Related]

  • 26. Overview of drug interactions with the quinolones.
    Davey PG.
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():97-107. PubMed ID: 3053579
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.
    Staib AH, Harder S, Fuhr U, Wack C.
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):289-3. PubMed ID: 2737798
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Quinolone-resistant Escherichia coli in the health area of a 650-bed hospital].
    Fernández Fernández A, Lantero Benedito M, Gastañares Hernando MJ, Undabeitia Santisteban E, Fernández Santos F, Castaño Rodríguez A, Gil Fabra J, Martínez Castellanos F, Otero Mauricio G.
    Actas Urol Esp; 1994 Jun; 18(6):634-8. PubMed ID: 7942213
    [Abstract] [Full Text] [Related]

  • 32. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA, Cuffini AM, Tullio V, Savoia D, Cavallo GP.
    G Batteriol Virol Immunol; 1986 Jun; 79(1-6):85-97. PubMed ID: 3479370
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R, Griggs D, Andrews JM.
    Rev Infect Dis; 1988 Jun; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Update on quinolone drug interactions.
    Hulisz D, Miller K.
    Am Pharm; 1990 Sep; NS30(9):34-6. PubMed ID: 2220561
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H, Quentin C, de Barbeyrac B, Bebear C.
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD, Felmingham D, Ridgway GL, Grüneberg RN.
    Drugs Exp Clin Res; 1985 May; 11(4):253-7. PubMed ID: 2941257
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.